Year: 2018
Interpretation of Dose-dependent Pharmacokinetics of Ruzasvir Using Both Physiologically-based Pharmacokinetic and Population Pharmacokinetic Modeling Approaches
Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy
Clinical Trial Simulation (CTS) for a New Rapidly Absorbed Paracetamol Formulation (NP) Development from the Conventional Paracetamol Tablet (CP)
Impact of Free Fatty Acids on Prediction of Unbound Fraction of Cefazolin and Diazepam in Plasma of Full-term Neonates
Application of Feto-maternal Physiologically-based Pharmacokinetic Model to Predict Emtricitabine Concentration During Pregnancy
Modeling Double Peak Phenomenon and In Vitro-In Vivo Correlation (IVIVC) in Pharmacokinetics (PK) for Clinical Trial Simulation (CTS) of Virtual Bioequivalence (BE) Studies
Development of a Population Pharmacokinetic Model for Binimetinib with Subsequent Exposure-response Analyses in NRAS Mutant Melanoma
A Product-profile-driven Clinical Utility Index (CUI) Analysis to Balance Benefits and Risks for Dose Selection in Oncology
Certara to Participate in 40 Pharmacometrics Modeling and Simulation Sessions at ACoP9
PRINCETON, NJ – Oct. 5, 2018 – Certara today announced that it is participating in 40 sessions at the ninth American Conference on Pharmacometrics (ACoP9).